Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a we...
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast ...
MSFT - We believe that Microsoft is on its way to accelerating cloud and AI monetization, which is going to comprise a bigger piece of Redmond going forward and will ultimately spur growth and margins over the coming years. While Anthropic has seen significant advancements in model performance and
A Closer Look at FY4Q25 (December) ResultsRevenueTotal revenue of $1.407 billion (up 70% y/y and 19% q/q) came in above both the company’s guidance range of $1.327 billion to $1.331 billion and the Street’s $1.340 billion estimate driven by the continued acceleration of its US business in both gove
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activi...
Warner Bros. Discovery, Inc. (WBD - $28.24) and Netflix Inc. (NFLX - $85.70)News Reports Senate Antitrust Panel Chair Raises Concerns Over Pending Merger. According to the WSJ, Senator Mike Lee, chairman of the Senate Judiciary Committee's Subcommittee on Antitrust, Competition Policy & Consume
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.